Oyagen, Inc.

Get Full Access

Description

  • OYAGEN is a biotechnology company formed on September 5, 2003, for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. OyaGen holds exclusive rights to important technologies originating from the University of Rochester Medical Center (URMC), the Thomas Jefferson University (TJU), and Oregon Health Science Center. Over the past decade, a series of research advances have identified two families of related enzymes known as Editing Enzymes. These enzymes are endogenous cellular proteins, which chemically alter RNA or DNA molecules and thereby change the genetic code. OyaGen believes that there is a significant opportunity to harness the editing process to create therapies for a number of disease states. OyaGens initial therapeutic focus is a novel approach to the treatment of Human Immunodeficiency Virus (HIV). This initial focus on HIV is driven by a series of ground breaking discoveries that: -Identified an Editing Enzyme present in immune system -Determined that HIV inhibits this Editing Enzyme as a vital part of the infection cycle -Demonstrated that allowing this Editing Enzyme to function halts HIV OyaGen will pursue several proprietary assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states. OyaGen offers method development and testing as a fee-for-service to academic/educational institutions and to industry. OyaGen staff will provide expert consulting services in assay development, biochemistry, structural biology, cell biology, virology for high throughput drug discovery, drug development as well as advice in preparing federal grants.
  • location

    Headquarters:77 Ridgeland Road , Henrietta, New York, United States

    More
  • Oyagen, Inc. phone

    Phone Number: +1 585-697-4351

  • Oyagen, Inc. website

    Website: https://www.oyageninc.com

  • Oyagen, Inc. employees

    Employees:4

  • Oyagen, Inc. revenue

    Revenue:$1 - 10M

  • Oyagen, Inc. legal name

    Legal Name:Oyagen, Inc.

  • Oyagen, Inc.'s Social Media

    Oyagen, Inc. linkedin Oyagen, Inc. facebook
  • done Is this data correct?
  • |  NAICS Code: 238990  |

    Show More
Person level website identification

Chief Operations Officer for Oyagen, Inc.

Tom Fitzgerald

Chief Operations Officer

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Tom Fitzgerald

Chief Operations Officer

Ryan Bennett

Chief Scientific Officer And Lab Director

Richard Mccloskey

Board Member

Frequently Asked Questions regarding Oyagen, Inc.

  • Where are Oyagen, Inc.'s Headquarters?

    Oyagen, Inc.'s Headquarters are in 77 Ridgeland Road ,Henrietta,New York,United States

  • What is Oyagen, Inc.'s phone number?

    Oyagen, Inc.'s phone number is +1 585-697-4351

  • What is Oyagen, Inc.'s official website?

    Oyagen, Inc.'s official website is https://www.oyageninc.com

  • What is Oyagen, Inc.'s Revenue?

    Oyagen, Inc.'s revenue is $1 - 10M

  • What is Oyagen, Inc.'s NAICS code?

    Oyagen, Inc.'s NAICS code is 238990

  • How many employees are working in Oyagen, Inc.

    Oyagen, Inc. has 4 employees

  • What is Oyagen, Inc.'s Industry?

    Oyagen, Inc. is in the industry of Pharmaceuticals

  • Who is Oyagen, Inc.'s Chief Operations Officer?

    Oyagen, Inc.'s Chief Operations Officer is Tom Fitzgerald

Company Directory